Jose Terencio
Board Member
Immunology
Cinfa Biotech
Spain
Biography
Dr. Terencio holds a Master in R+D of Drugs by the University of Navarra, a PhD in CNS Pharmacology by the University of Barcelona, as well as a Development Management Program (PDD) by IESE Business School. He has more than 17 years of experience in the Biopharmaceutical industry holding several positions. Before joining Grifols, he was in charge of the Biochemistry and Molecular Biology Department in the Drug Discovery Area for Grupo Ferrer. In 2008 he was appointed at Grifols as R+D Director of one of the subsidiaries, Laboratorios Grifols. Two years later, he became the COO at Gri-Cel, a new subsidiary of Grifols aimed to invest in advanced therapies as well as innovative therapeutic approaches. During his professional career, Dr. Terencio has worked in several therapeutic areas, CNS, Cardiovascular, Oncology and Infectious Diseases. His main scientific expertise is within the field of Drug Discovery and Development of Small Molecules. In the last few years, as COO of Gri-Cel his focus has moved into the assessment and management of projects involving Biotech companies, specifically those related with innovative therapies. Dr. Terencio holds a Master in R+D of Drugs by the University of Navarra, a PhD in CNS Pharmacology by the University of Barcelona, as well as a Development Management Program (PDD) by IESE Business School. He has more than 17 years of experience in the Biopharmaceutical industry holding several positions. Before joining Grifols, he was in charge of the Biochemistry and Molecular Biology Department in the Drug Discovery Area for Grupo Ferrer. In 2008 he was appointed at Grifols as R+D Director of one of the subsidiaries, Laboratorios Grifols. Two years later, he became the COO at Gri-Cel, a new subsidiary of Grifols aimed to invest in advanced therapies as well as innovative therapeutic approaches. During his professional career, Dr. Terencio has worked in several therapeutic areas, CNS, Cardiovascular, Oncology and Infectious Diseases. His main scientific expertise is within the field of Drug Discovery and Development of Small Molecules. In the last few years, as COO of Gri-Cel his focus has moved into the assessment and management of projects involving Biotech companies, specifically those related with innovative therapies.
Research Interest
molecular developmental biology and stem cell research advanced therapies as well as innovative therapeutic approaches.
